Showing 1–25 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Soedarsono Soedarsono
… prolonged QT side effects are also neededto prevent switch regimens that can affect the patient’s psychological condition.
Katherine Cobb, Aline Wilson, Nikolas Rae, Neil Stevenson
…fety data is awaited, compassionate use of alternative drug regimens within strict monitoring guidelines should be considered.
Tsong H. Chang, Yuxia Zhang, Yanming Sun, Zhiyuan Zhao, Fengxia Liu, et al.
…(RR) TB patients who were switched to contezolid-containing regimens due to adverse reactions during treatment with linezolid-containing regimens were included. Linezolid was administered 600mg once daily for 6-24 weeks, contezolid was given 400mg twice daily for 4 months to 1 ye…
Soumana Boubacar Soumana, Abdourahamane Yacouba, Cheikh Aboubacar Abdoul Lawi, Ibrahim Oumar, Bassirou Souleymane, et al.
Background The emergence of extensively drug-resistant tuberculosis (XDR-TB) poses a serious challenge to global tuberculosis control, particularly in high-burden countries like Niger. In 2021, a new fully oral, shorter treatment regimen, named regimen C, was adopted nationally. …
Tushar R. Sahasrabudhe
… Revised National TB Control Programme (RNTCP) as DOTS plus regimens. These regimens involved use of less potent second-line drugs which were at least 5 and up to 7 in number based on grouping of medicines, and were required to be taken for a longer duration, often ranging from 1…
Nirmal Kumar Jain
…ed guidelines published in March 2020 recommends fully oral regimens for drug-resistant tuberculosis (DR-TB) that is isoniazid-resistant TB, rifampicin-resistant TB (RR-TB), multi-DR-TB (MDR-TB), and extensively DR-TB (XDR-TB). These regimens are said to be game changer for these…
Durga Balagopalan
All oral regimens have become a great advancement in the treatment of multidrug-resistant tuberculosis (MDR-TB). Earlier, the treatment of MDR-TB was considered long, with side effects and more relapse rate. The best estimate of the proportion of people diagnosed with MDR/Rifampi…
sha wei
…osis infection, we identified several new experimental drug regimens among billions of possible drug-dose combinations that outperform the current Standard Regimen. We used the PRS platform to optimize the in vivo drug doses of novel regimens (designated PRS regimen) in a mouse m…
Oki Nugraha Putra, Telly Purnamasari
…t tuberculosis (XDR-TB) and MDR-TB[3]. It demonstrates that regimens containing pretomanid and BPaL or BPaLM were associated with favorable outcomes (cured). BPaLM consists of bedaquiline (400 mg once daily for the initial two weeks, followed by 200 mg thrice weekly for 22 weeks)…
Wenhong Zhang, PhD,MD
…or MDR-TB treatment success rates suggest that current drug regimens are suboptimal. In addition, they are costly with a high pill burden, as many drugs, with significant potential for adverse events, are given for a long duration. These factors also inhibit good treatment compli…
Kavitha Saravu, Madhukar Pai
…drugs (e.g. bedaquiline) as well as shorter, individualized regimens, based on DST results.[2] In a study published in this issue of Lung India, Singh et al. reported on the treatment outcomes of a modified DOTS-plus strategy among 98 consecutive culture-proven adult MDR-TB patie…
Malik Zohaib Ali, Taru S. Dutt, Amy L. MacNeill, Amanda Walz, Camron Pearce, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Malik Zohaib Ali, Taru S Dutt, Amy MacNeill, Amanda Walz, Camron Pearce, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Malik Zohaib Ali, Taru S Dutt, Amy MacNeill, Amanda Walz, Camron Pearce, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Bavesh D Kana
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Malik Zohaib Ali, Taru S Dutt, Amy MacNeill, Amanda Walz, Camron Pearce, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Malik Zohaib Ali, Taru S. Dutt, Amy L. MacNeill, Amanda Walz, Johnathan Patterson, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the Balb/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Bavesh D Kana
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the Balb/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Malik Zohaib Ali, Taru S. Dutt, Amy L. MacNeill, Amanda Walz, Johnathan Patterson, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the Balb/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Malik Zohaib Ali, Taru S. Dutt, Amy L. MacNeill, Amanda Walz, Johnathan Patterson, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the Balb/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Malik Zohaib Ali, Taru S. Dutt, Amy L. MacNeill, Amanda Walz, Camron Pearce, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Wenhong Zhang, PHD
…l to evaluate the efficacy and safety of seven 9-month oral regimens compared to a 9-month standard of care (SOC) regimen in RR-TB participants susceptible to fluoroquinolones, and a bedaquiline-containing 9-month oral regimen compared to a 20-month conventional regimen in RR-TB …
Rashmi Ratnam, Parul Jain, Ram Awadh Singh Kushwaha, Amita Jain, Urmila Singh, et al.
…the World Health Organization (WHO) recommends two all-oral regimens for rifampicin-resistant (RR), multidrug-resistant (MDR), and extensively drug-resistant (XDR) TB: a longer M/XDR-TB regimen (18–20 months) and a shorter bedaquiline-containing MDR/RR-TB regimen (9–11 months). T…
Y. I. Feshchenko, N.А. Lytvynenko, L.M. Protsyk, M.V. Pohrebna, Yu.О. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for sel…
Y. I. Feshchenko, N.А. Lytvynenko, L.M. Protsyk, M.V. Pohrebna, Yu.О. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for sel…